Navigation Links
ISIS Initiates Phase 1 Clinical Trial of ISIS-SOD1Rx in Patients With ALS
Date:3/5/2010

CARLSBAD, Calif., March 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).  Approximately 20 percent of all familial ALS cases are caused by a mutant form of superoxide dismutase, or SOD1.  ISIS-SOD1Rx is an antisense drug designed to inhibit the production of SOD1.  The ALS Association and the Muscular Dystrophy Association are providing funding for the development of ISIS-SOD1Rx.  

"There is a desperate need for new and more substantive treatments for ALS patients.  The mission of the Northeast ALS Consortium is to help advance new therapeutic options for patients with ALS, and I am very pleased to be a co-chair on this important study evaluating ISIS-SOD1Rx in people with familial ALS," said Merit Cudkowicz, M.D., Co-Chair of the Northeast ALS Consortium and a Professor of Neurology at the Massachusetts General Hospital of Harvard Medical School.

"It is evident that certain cases of familial ALS are related to mutant forms of SOD1.  Therefore, the selective inhibition of SOD1 production could provide a way to improve the outcomes of these patients with ALS," said Timothy Miller, M.D., Ph.D., Assistant Professor of Neurology at Washington University School of Medicine and Director of the Christopher Wells Hobler Laboratory for ALS Research at the Hope Center for Neurological Disorders.  "This is the first study to administer an inhibitor of SOD1 directly into the central nervous system.  Having been involved with Isis in the research and now the clinical development of ISIS-SOD1Rx, I am looking forward to co-chairing this study with Dr. Cudkowicz and the Northeast ALS Consortium."

"ISIS-SOD1Rx is our first antisense drug to enter clinical trials to treat a neurodegenerative disease and our first antisense drug to be administered directly into the central nervous system.  Based on our earlier preclinical studies, we believe that ISIS-SOD1Rx could offer an effective treatment for patients with familial ALS," said C. Frank Bennett, Ph.D., Senior Vice President of Research at Isis Pharmaceuticals.  "This study is the first step in demonstrating the applicability of antisense drugs to treat severe neurodegenerative diseases.  We also continue to advance our earlier-stage programs toward human studies."  

The Phase 1 study of ISIS-SOD1Rx is a placebo-controlled, dose-escalation study designed to assess the safety, tolerability and pharmacokinetic profile of ISIS-SOD1Rx in patients with familial ALS that is caused by mutations within the SOD1 gene.  The study consists of four cohorts with eight patients each.  In this study, ISIS-SOD1Rx will be administered intrathecally using an external pump to deliver the drug directly into the spinal fluid during a single, 12-hour infusion.  The study will be conducted in multiple centers within the United States.  

"This therapy will be the first treatment for ALS that is specifically aimed at the target, SOD1, known to cause ALS. The development of new treatments for ALS is an extremely challenging and costly process.  The ALS Association has been pleased to co-fund this study and partner with Isis on this extremely promising treatment approach. It is only through the support of our generous donors that this type of advancement is made possible," commented Lucie Bruijn, Ph.D., Chief Scientist, The ALS Association.

"This is a watershed moment," said R. Rodney Howell, M.D., Chairman of the MDA Board of Directors. "More than 30 people with familial ALS caused by mutations in the SOD1 gene soon will receive infusions of a SOD1 inhibitor directly into their central nervous systems."  Dr. Howell added that "MDA has invested more than $270 million fighting ALS, and it's exciting to see an excellent dose-escalation study get underway to assess the safety of ISIS-SOD1Rx."

ABOUT ISIS-SOD1Rx

ISIS-SOD1Rx is designed to inhibit the production of SOD1.  In preclinical studies, Isis, in collaboration with Timothy Miller, Don Cleveland (University of California, San Diego), and Richard Smith (Center for Neurological Study) were able to lower production of SOD1 with ISIS-SOD1Rx in neurons and surrounding cells and prolong life in rats that showed many symptoms of ALS.  In December 2007, the FDA granted ISIS-SOD1Rx Orphan Drug designation for the treatment of ALS. Because antisense drugs do not cross the blood-brain barrier, a small pump administers the drug directly into the central nervous system infusing the drug into the cerebral spinal fluid. Clinicians call this type of administration intrathecal infusion.  As part of Isis' alliance with Genzyme, Genzyme has a right of first negotiation to license ISIS-SOD1Rx from Isis.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis' discovery and development of drugs for neurodegenerative diseases, and the development, activity, therapeutic potential and safety of ISIS-SOD1Rx in the treatment of ALS.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009, which is on file with the SEC.  Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.

SOURCE Isis Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.isispharm.com

'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
4. Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui
5. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
6. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
7. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
8. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
11. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... 2016 Summary Breast cancer, a malignant ... most common cancer in women worldwide, accounting for 16% ... The number of women diagnosed with breast cancer has ... of deaths has declined due to earlier diagnosis and ... revolutionized in the past four decades, especially with increasing ...
(Date:2/4/2016)... International Inc. (NYSE: MTD ) today announced fourth ... , Sales in local currency increased 3% ... sales decreased 3% as currency reduced sales growth by ... diluted share as reported (EPS) were $4.44, compared with ... $4.65, an increase of 10% over the prior-year amount ...
Breaking Medicine Technology:
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 ... ... today announced the availability of the company's lighter, sleeker next generation LYNX VR ... assembly plant. , Improvements in design and manufacturing not only reduce the ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... Miami, FL (PRWEB) , ... February 05, 2016 ... ... of the largest domestic franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th ... and awareness for kids and adults with muscular dystrophy, ALS and related diseases ...
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute ... at the tips of your toes. Foot massage, whether administered by a professional masseuse ... and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) has ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon and ... cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery ... three-year term as chief and began a second three-year term in January of 2016. ...
Breaking Medicine News(10 mins):